Page 100 - CUA KIDNEY CANCER HANDBOOK 2020
P. 100
IRRC Independent radiology review committee
ITT Intent-to-treat
KC Kidney cancer
KCRNC Kidney Cancer Research Network of Canada
KPS Karnofsky performance status
LH Luteinizing hormone
mRCC Metastatic renal cell carcinoma
MRCP Magnetic resonance cholangiopancreatography
mTOR Mammalian target of rapamycin
NE Not evaluable
NR Not reached
NYHA New York Heart Association
ORR Overall response rate
OS Overall survival
PCP Pneumocystis pneumonia
PD Progressive disease
PD-1 Programmed death 1
PD-L1 Programmed death ligand 1
PFS Progression-free survival
PgP P-glycoprotein
PPES Palmar-plantar erythrodysesthesia syndrome
PR Partial response
RCC Renal cell carcinoma
RECIST Response Evaluation Criteria In Solid Tumors
RT Radiotherapy
SD Stable disease
SJS Stevens-Johnson syndrome
SRT Stereotactic radiotherapy
T3 Triiodothyronine
T4 Thyroxine
TB Tuberculosis
TEN Toxic epidermal necrolysis
TKI Tyrosine kinase inhibitor
TNF Tumor necrosis factor
TSH Thyroid stimulating hormone
TTF Time to treatment failure
ULN Upper limit of normal
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
82 Practical Approaches to Managing Advanced Kidney Cancer
